Semin Thromb Hemost 2016; 42(02): 095-101
DOI: 10.1055/s-0035-1564830
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Use of Plasma for Acquired Coagulation Factor Deficiencies in Critical Care

Akshay Shah
1   Nuffied Division of Anaesthetics, John Radcliffe Hospital, Oxford, United Kingdom
,
Stuart McKechnie
1   Nuffied Division of Anaesthetics, John Radcliffe Hospital, Oxford, United Kingdom
,
Simon Stanworth
2   Oxford University Hospitals NHS Trust/NHS Blood & Transplant, John Radcliffe Hospital, Oxford, United Kingdom
› Author Affiliations
Further Information

Publication History

Publication Date:
30 December 2015 (online)

Abstract

Coagulopathy in critically ill patients is common and often multifactorial. Fresh frozen plasma (FFP) is commonly used to correct this either prophylactically or therapeutically. FFP usage is mainly guided by laboratory tests of coagulation, which have been shown to have poor predictive values for bleeding. Viscoelastic tests are an attractive option to guide hemostatic therapy, but require rigorous evaluation. The past few years have seen a gradual reduction in national use of FFP potentially due to an increased awareness of risks such as transfusion-related acute lung injury, patient blood management strategies to reduce transfusion in general, and increased awareness of the lack of high-quality evidence available to support FFP use. Within critical care, FFP is administered before invasive procedures/surgery, to treat major traumatic and nontraumatic hemorrhage, disseminated intravascular coagulation, and for urgent warfarin reversal if first-line agents, such as prothrombin complex concentrate (PCC) are not available. Alternative agents such as fibrinogen concentrate and PCC need further evaluation through large-scale clinical trials.

 
  • References

  • 1 Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10 (4) 222
  • 2 Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38 (2, Suppl): S26-S34
  • 3 Warren BL, Eid A, Singer P , et al; KyberSept Trial Study Group. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001; 286 (15) 1869-1878
  • 4 Ranieri VM, Thompson BT, Barie PS , et al; PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012; 366 (22) 2055-2064
  • 5 O'Shaughnessy DF, Atterbury C, Bolton Maggs P , et al; British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126 (1) 11-28
  • 6 Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. Hematology (Am Soc Hematol Educ Program) 2007; (1) 179-186
  • 7 AABB, America's Blood Centers, American Red Cross, Armed Services Blood Program. Circular of Information for the Use of Human Blood and Blood Components. Bethesda, MD: AABB, 2013. Available at: http://www.aabb.org/tm/coi/Documents/coi1113.pdf . Accessed May 20, 2015
  • 8 Shehata N, Blajchman M, Heddle N. Coagulation factors in FFP and cryosupernatant. Transfus Med 2001; 11: 391-401
  • 9 Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic function after all?. Transfusion 2006; 46 (10) 1836-1844
  • 10 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (6) 958-965
  • 11 Segal JB, Dzik WH ; Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45 (9) 1413-1425
  • 12 Stanworth SJ, Walsh TS, Prescott RJ, Lee RJ, Watson DM, Wyncoll D ; Intensive Care Study of Coagulopathy (ISOC) investigators. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care 2011; 15 (2) R108
  • 13 Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet 2002; 359 (9300) 47-48
  • 14 Royston D, von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth 2001; 86 (4) 575-578
  • 15 Afshari A, Wikkelsø A, Brok J, Møller AM, Wetterslev J. Thrombelastography (TEG) or thromboelastometry (ROTEM) to monitor haemotherapy versus usual care in patients with massive transfusion. Cochrane Database Syst Rev 2011; 16 (3) CD007871
  • 16 Hunt H, Stanworth S, Curry N , et al. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) for trauma induced coagulopathy in adult trauma patients with bleeding. Cochrane Database Syst Rev 2015; 2: CD010438
  • 17 Serious Hazards of Transfusion Annual Report 2013 Available at: http://www.shotuk.org/wp-content/uploads/74280-SHOT-2014-Annual-Report-V12-WEB.pdf . Accessed May 30, 2015
  • 18 Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012; 52 (8) 1673-1686 , quiz 1673
  • 19 Karam O, Tucci M, Combescure C, Lacroix J, Rimensberger PC. Plasma transfusion strategies for critically ill patients. Cochrane Database Syst Rev 2013; 12: CD010654
  • 20 Müller MC, Arbous MS, Spoelstra-de Man AM , et al. Transfusion of fresh-frozen plasma in critically ill patients with a coagulopathy before invasive procedures: a randomized clinical trial (CME). Transfusion 2015; 55 (1) 26-35 , quiz 25
  • 21 Müller MCA, Straat M, Meijers JCM , et al. Fresh frozen plasma transfusion fails to influence the hemostatic balance in critically ill patients with a coagulopathy. J Thromb Haemost 2015; 13 (6) 989-997
  • 22 Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125 (1) 69-73
  • 23 Hunt BJ. Bleeding and coagulopathies in critical care. N Engl J Med 2014; 370 (9) 847-859
  • 24 Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston EF. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997; 77 (3) 477-480
  • 25 Goldstein JN, Refaai MA, Milling Jr TJ , et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet 2015; 385 (9982) 2077-2087
  • 26 Guest JF, Watson HG, Limaye S. Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United kingdom. Clin Ther 2010; 32 (14) 2478-2493
  • 27 Toh CH, Hoots WK ; SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007; 5 (3) 604-606
  • 28 Levi M, Toh CH, Thachil J, Watson HG ; British Committee for Standards in Haematology. Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145 (1) 24-33
  • 29 Wada H, Thachil J, Di Nisio M , et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost 2013; 11: 761-767
  • 30 Stainsby D, MacLennan S, Thomas D, Isaac J, Hamilton PJ ; British Committee for Standards in Haematology. Guidelines on the management of massive blood loss. Br J Haematol 2006; 135 (5) 634-641
  • 31 Cap A, Hunt BJ. The pathogenesis of traumatic coagulopathy. Anaesthesia 2015; 70 (Suppl. 01) 96-101 , e32–e34
  • 32 Waters JH. Role of the massive transfusion protocol in the management of haemorrhagic shock. Br J Anaesth 2014; 113 (Suppl. 02) ii3-ii8
  • 33 Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee (JPAC). 7.3: Transfusion management of major haemorrhage. Available at: http://www.transfusionguidelines.org.uk/transfusion-handbook/7-effective-transfusion-in-surgery-and-critical-care/7-3-transfusion-management-of-major-haemorrhage . Accessed June 1, 2015
  • 34 Holcomb JB, Tilley BC, Baraniuk S , et al; PROPPR Study Group. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA 2015; 313 (5) 471-482
  • 35 Schöchl H, Voelckel W, Schlimp CJ. Management of traumatic haemorrhage—the European perspective. Anaesthesia 2015; 70 (Suppl. 01) 102-107 , e35–e37
  • 36 Pandey S, Vyas GN. Adverse effects of plasma transfusion. Transfusion 2012; 52 (Suppl. 01) 65S-79S
  • 37 Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA ; TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005; 19 (1) 2-31
  • 38 Holness L, Knippen MA, Simmons L, Lachenbruch PA. Fatalities caused by TRALI. Transfus Med Rev 2004; 18 (3) 184-188
  • 39 Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14 (6) 682-687
  • 40 Li G, Rachmale S, Kojicic M , et al. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2011; 51 (2) 338-343
  • 41 Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. Br J Anaesth 2013; 110 (5) 764-772
  • 42 Kozek-Langenecker SA, Afshari A, Albaladejo P , et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013; 30 (6) 270-382
  • 43 Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus 2010; 8 (3) 149-154
  • 44 Gill R. Practical management of major blood loss. Anaesthesia 2015; 70 (Suppl. 01) 54-57 , e19–e20
  • 45 Schöchl H, Nienaber U, Hofer G , et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14 (2) R55
  • 46 Görlinger K, Dirkmann D, Hanke AA , et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. Anesthesiology 2011; 115 (6) 1179-1191